Drugs / KJ017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06604546 | Mar → May 2024 | — | Shanghai Bao Pharmaceuticals Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KJ017 | “KJ017, a rHuPH20, in healthy participants receiving gravity-driven SC infusion.” PMID 41935547 ↗ Apr 2026 |
| Modality | Protein / enzyme biologic | “Recombinant human hyaluronidase PH20 (rHuPH20)” PMID 41935547 ↗ Apr 2026 |
| Route | Subcutaneous | “Recombinant human hyaluronidase or placebo was injected subcutaneously at the prescribed site on the day of administration.” NCT06604546 ↗ |